About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Research Stresses on Curbing Cystic Kidney Growth

by Kathy Jones on November 6, 2012 at 8:53 PM
Font : A-A+

 Research Stresses on Curbing Cystic Kidney Growth

One of the most common genetic disorders known to man is the autosomal-dominant polycystic kidney disease (ADPKD), which affects one in every 1,000 people. It is also responsible for up to ten percent of patients on dialysis worldwide.

The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications. Although we have known about the disease for over a century and its genetic basis for almost 20 years, there was no effective treatment until now.

Advertisement

Kidneys stopped growing"Our study highlights a potential treatment that reduces kidney growth and the associated symptoms and slows the decline in kidney function," explains Professor Olivier Devuyst from the Institute of Physiology at the University of Zurich - one of the chief researchers in the phase-three clinical trial just published in the New England Journal of Medicine.

Over 1,400 patients were given tolvaptan over a three-year period at 129 centers worldwide. The drug is a selective V2 vasopressin receptor antagonist that lessens the effect of the antidiuretic (urine-concentrating) vasopressin hormone and increases urination.
Advertisement

The researchers studied whether tolvaptan slows the progression of the kidney disease by slowing the cyst growth. "The study achieved its goal," explains Professor Devuyst. In patients who received tolvaptan for three years instead of the placebo, the entire kidney volume decreased with fewer complications resulting from the disease, the pain eased off and the decline in kidney function was slowed. Adverse events such as increased urination and thirst as well as increased liver enzymes and blood sodium level were apparent.

15-year research projectThe study is the culmination of 15 years of research done by several research groups including that of Olivier Devuyst. They began by examining transport mechanisms in cells that coat the cysts and, in particular, identified the pathway of the V2 vasopressin receptor as a potential trigger for cystic kidney disease. The demonstration that blocking this receptor slows the disease and improves the kidney function in various animal models provided the rationale for the intervention study with tolvaptan.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Are Menopause Symptoms Troubling You?: Try these Options
Vaccination  And Counter  Measures Against  Monkeypox
Indian Railways Special Concession on Health Grounds
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Urinary Stones In Children Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Kidney Disease Kidney Kidney Health Stones in Urinary Tract Renal Tubular Acidosis Kidney Biopsy Prevention of Kidney Disease 

Most Popular on Medindia

Pregnancy Confirmation Calculator Blood Pressure Calculator Loram (2 mg) (Lorazepam) Find a Doctor Turmeric Powder - Health Benefits, Uses & Side Effects Selfie Addiction Calculator How to Reduce School Bag Weight - Simple Tips Color Blindness Calculator Drug - Food Interactions Daily Calorie Requirements

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use